Therapy for advanced stages of Parkinson's disease
- Authors: Karakulova Y.V.1, Golchenko E.A.2
-
Affiliations:
- E. A. Vagner Perm State Medical University
- V.I. Voinov Orenburg Regional Clinical Hospital
- Issue: Vol 41, No 4 (2024)
- Pages: 70-79
- Section: Review of literature
- Submitted: 14.05.2024
- Accepted: 26.08.2024
- Published: 03.10.2024
- URL: https://permmedjournal.ru/PMJ/article/view/631775
- DOI: https://doi.org/10.17816/pmj41470-79
- ID: 631775
Cite item
Full Text
Abstract
The search and analysis of data on treatment options of advanced stages of Parkinson's disease from various scientific sources on biomedical research PubMed in the Medline, Russian scientific electronic library CyberLeninka databases are summarized in the article. A comparison of data was performed to highlight the main directions of modern approaches to the treatment of advanced stages of Parkinson's disease. To treat the disease at a late stage with pronounced motor fluctuations in the form of “off” symptoms and painful dyskinesias during the “on” period, invasive and non-invasive high-tech methods of treatment are used. The most relevant method of treatment for Parkinson's disease in patients with a long history of the disease and side symptoms of traditional medicinal methods of correction are the use of Duodopa - levodopa/carbidopa intestinal gel (LCIG). It is important to note that the increased "on" period can allow people with advanced Parkinson's disease to raise motor activity, thereby improving their independence in daily activities from other people.
Full Text
Introduction. Parkinson's disease is the second most common after Alzheimer's disease, a steadily progressive neurodegenerative disease associated with dopamine deficiency. [1]. Prevalence: 160 cases per 100 thousand population. The prevalence increases with age. Recently, the disease has become more common in people under 50 years of age [2, 3].
The diagnosis of Parkinson's disease is made clinically when oligobradykinesia is combined with resting tremor or rigidity and includes both motor and non-motor manifestations (visual impairment, sleep disorder, neuropsychiatric and autonomic disorders, cognitive deficit). The progression of the disease is variable, and an accurate prognosis cannot be established [4]. There are 5 stages in the structure of Parkinson's disease. According to the Delphi Consensus (2015), stages with postural disturbances, mainly 3 and 4, are considered advanced. Experts have put forward motor, non-motor and functional symptoms that signal the presence of an advanced stage of the disease in the patient [5]. Of the motor symptoms, these include moderately pronounced motor fluctuations that bother the patient, among which there should be symptoms of “off” for 2 or more hours and dyskinesia for 1 or more hours a day, dysphagia that bothers the patient after taking levodopa medications 5 times. The group of experts included cognitive impairment in the stage of mild dementia, disturbing hallucinations and psychotic disorders, the presence of fluctuations in non-motor symptoms and moderate sleep disturbances as non-motor symptoms of advanced stages. Functional symptoms include patient falls that are repeated despite treatment, difficulties in independently solving complex problems, and constant outside help to maintain activity due to impaired ability to move independently [5].
Currently, levodopa drugs are the “gold standard” in the treatment of Parkinson’s disease, but they are not able to stop the progression of the disease. Levodopa is a precursor of dopamine, the deficiency of which underlies the mechanism of development of PD. Unlike dopamine, levodopa is able to penetrate the brain through the blood-brain barrier, where it undergoes decarboxylation, as a result of which it is converted into dopamine, replenishing the deficiency [6].
The introduction of levodopa into clinical practice over 50 years has revolutionized the treatment of parkinsonism [7].
As the neurodegenerative process progresses, the number of neurons in the substantia nigra decreases. In the surviving neurons, dopamine metabolism accelerates. Neighboring glial cells and nondopaminergic neurons begin to participate in the synthesis of dopamine, which they are not able to store, resulting in an excessive release of dopamine into the synaptic cleft after each dose of a levodopa-containing drug. The physiological tonic work of dopamine receptors changes to pulsating, as a result of which a distortion of the sensitivity of dopamine receptors develops [6].
After 4-5 years of taking levodopa, 80% of patients experience side effects associated with taking levodopa-containing drugs (as a result of narrowing of the therapeutic window), in the form of drug-induced dyskinesias and motor fluctuations. In this regard, the danger of worsening postural disorders in the form of falls increases, which leads to traumatization of patients and an increase in the degree of disability [8].
The proposal to outline the circle of patients with advanced stages of PD was formulated by Swedish neurologists and included the duration of the disease for more than 5 years, taking antiparkinsonian drugs at least 5 times a day, the presence of the phenomenon of “dose exhaustion”, “off” symptoms, dyskinesias or dystonia for at least 2 h during the day. A little later, as part of the Navigate PD educational program, they came to specific criteria for treatment with invasive methods: patients taking levodopa drugs more than 5 times a day, having “off” periods lasting more than 1–2 hours during the period of wakefulness (despite optimally selected therapy ), as well as disabling dyskinesias that are not relieved by taking amantadine at a dose of more than 400 mg/day. Moreover, the duration of the disease less than 4 years is not an obstacle to invasive treatment methods [9].
Functional methods are recommended for patients with depleted drug reserve or side effects from antiparkinsonian drugs.
In the treatment of movement disorders, 3 functional methods are used: ablative, or destructive, surgery (thalamotomy, pallidotomy); deep brain stimulation (DBS); superficial invasive brain stimulation (for example, extradural or subdural stimulation of the motor cortex) and non-invasive (transcranial magnetic stimulation) [10].
For patients with Parkinson's disease who do not achieve positive dynamics in terms of correction of motor disorders during drug therapy, alternative methods until now have been radiofrequency thalamotomy, radiosurgical thalamotomy and DBS [11].
Over the past 20 years, electrical stimulation of deep brain structures has been an effective method for correcting complications of levodotherapy in patients with Parkinson's disease. The subthalamic nucleus is the best target for the effectiveness of this method [12].
The knowledge accumulated in recent decades in the field of neurodegeneration has opened new horizons in the treatment of Parkinson's disease. In 2014, the first experience in treating Parkinson's disease using magnetic resonance imaging-guided focused ultrasound (MR-FUS) was published. In 2017, the results of the first randomized, double-blind study of the effectiveness of MR-FUS in Parkinson's disease were presented [13].
For the first time in the Russian Federation, thalamotomy was performed using MR-FUS on May 5, 2020, at the Clinic of Intellectual Neurosurgery of the International Medical Center named after. V.S. Buzaev in Ufa [14]. The advantages of the method are non-invasiveness (without craniotomy), single procedure, constant contact between the doctor and the patient due to the absence of general anesthesia, obtaining results during the procedure or immediately after its completion, no need for hospitalization, the possibility of reversible effects at the first stage of therapy [15, 16]. Destruction of the subcortical nuclei using MR-FUS has become a good alternative for patients with contraindications to DBS and with asymmetric symptoms. In addition, the patient does not need to correct stimulation parameters or replace the battery as with DBS [17, 18]. However, one should remember about the possible complications of this method: impaired walking, balance, sensitivity.
A limitation of MR-FUS as a destructive procedure is its use in unilateral surgeries. However, scientists from Switzerland reported the results of monitoring patients with PD after bilateral pallidothalamic tractotomy and this issue is now being reconsidered [19].
It should be noted that an effective invasive method for treating advanced stages of Parkinson's disease is the drug Duodopa - levodopa/carbidopa intestinal gel (LCIG). One LKIG cassette contains 100 ml of gel. 1 ml of gel contains 20 mg of levodopa and 5 mg of carbidopa monohydrate. Using a special pump, the gel passes through the gastrojejunal tube into the jejunum behind the ligament of Treitz, where levodopa is absorbed. This allows levodopa to be delivered directly to the jejunum, avoiding gastric dysmotility [20].
Levodopa/carbidopa intestinal gel is recommended for patients with Parkinson's disease in advanced stages, complicated by long-term use of levodopa in the form of motor fluctuations and drug dyskinesias, with insufficient effectiveness of other groups of antiparkinsonian drugs [21].
Existing clinical data indicate that the positive effect of LCIG persists for a long time (from 4 to 7 years) [22].
At the Center for Extrapyramidal Pathology and Botulinum Therapy of the Republic of Tatarstan (Kazan), 20 patients with advanced stages of PD were observed who received LCIG in the form of Duodopa gel. As a result of the use of LCIG therapy, the following conclusions were made: there was a statistically significant shortening of the “off” periods and an extension of the “on” periods without increasing dyskinesia, stable positive dynamics were noted on the UPDRS scale; A sustainable shortening of “off” periods by more than 70% was achieved [23].
Later, the Russian experience was generalized in a prospective open-label 54-week study (48 patients, 3 centers) [24].
The purpose of another significant study, COSMOS, was to study the effect of LCIG therapy on reducing polypharmacy in the treatment of advanced stages of PD. A total of 409 patients from 14 countries were included. The use of additional drugs decreased over time with all LCIG regimens, as the average duration of the “off” period and the duration of dyskinesias decreased [25].
Another study conducted by a group of researchers led by X.R. Zhan testified to the positive results of using levodopa gel. A meta-analysis comparing the effectiveness and safety of LCIG in comparison with the tablet form of levodopa showed that LCIG had a better therapeutic effect compared to oral drugs [26].
Long-term results of daily levodopa gel administration in patients with Parkinson's disease for 54 weeks after pump placement were published by Florida researchers in 2022. Longitudinal analysis of daily patterns confirms the long-term effectiveness of intestinal levodopa gel in increasing time to onset of ON-woTD after awakening, improve control of motor symptoms and reduce sudden fluctuations throughout the day. The findings confirm that LCIG provides continuous dopaminergic stimulation throughout patients' 16 hours of wakefulness and also improves the predictability of motor states, allowing patients to control motor symptoms, which significantly improves quality of life [27].
Improvements in Parkinson's disease sleep scores of 14% were noted in a retrospective study of patients receiving LCIG for 24 months, in addition to a 30% reduction in nocturnal motor symptoms [28].
In addition, a study was conducted among patients who had side effects from dopaminergic therapy in the form of impulsive-compulsive disorders (for example, gambling addiction) who received LCIG. It was noted that the severity of these manifestations decreased to 64% during 6 months of observation. This may be due to a decrease in the amount of dopamine receptor agonists taken [27].
More recently, a prospective, open-label study of 12 patients followed for 6 months showed that LCIG improved quality of life not only for patients but also for their family members [29].
In the world, the practice of using LCIG for PD is about 19 years old. The drug was registered in 2004 in Sweden. Levodopa/carbidopa intestinal gel (LCIG; carbidopa/levodopa enteral suspension) has been widely used and studied for the correction of motor fluctuations in patients with Parkinson's disease (PD) responding to levodopa therapy when other methods have failed [30].
There are conflicting opinions about starting the use of levodopa gel. Previously, it was believed that older age was preferable for starting LCIG; now, there are suggestions that in patients with a short history of the disease and early use, LCIG is more effective [31]. These results are partially confirmed. As a result of a retrospective analysis of 177 patients, it was confirmed that in those with a disease duration <10 years, the reduction in “off” time was greater than in those whose disease duration exceeded 10 years [32].
However, there are safety concerns with the use of levodopa/carbidopa enteric gel, which are primarily related to the procedure or device itself. Complications associated with the device include accidental removal, occlusion, migration, or kinking of the tube [33, 34]. Complications associated with the procedure itself were less common: stomatitis, inflammation [35]. The literature also indicates complications associated with LCIG, such as hallucinations, sleep disturbances and weight loss [36].
Conclusions. Thus, patients with advanced stages of PD, complicated by long-term use of levodopa, with pronounced motor fluctuations and drug-induced dyskinesias, have the opportunity to choose a non-oral method of treating the disease. It is important to note that LCIG (Duodopa gel) is highly effective, well tolerated and has a favorable safety profile over a long period of observation. A personalized approach will allow you to optimize the dose of levodopa gel for each patient, thereby helping to increase the effectiveness of this method. However, the use of DBS or levodopa/carbidopa intestinal gel pumps remains limited, largely due to the lack of availability and invasiveness of these technologies.
About the authors
Yu. V. Karakulova
E. A. Vagner Perm State Medical University
Author for correspondence.
Email: julia.karakulova@mail.ru
ORCID iD: 0000-0002-7536-2060
DSc (Medicine), Professor, Head of the Department of Neurology and Medical Genetics
Russian Federation, PermE. A. Golchenko
V.I. Voinov Orenburg Regional Clinical Hospital
Email: julia.karakulova@mail.ru
ORCID iD: 0000-0003-3954-1405
Neurologist
Russian Federation, OrenburgReferences
- Рабаданова Е.А., Гельпей М.А., Гончарова З.А. Немоторные симптомы болезни Паркинсона, их структура и влияние на качество жизни пациентов. Практическая медицина 2015; 5 (90): 111–115 / Rabadanova E.A., Gelpei M.A., Goncharova Z.A. Non-motor symptoms of Parkinson's disease, their structure and impact on the quality of life of patients. Practical medicine 2015; 5 (90): 111–115 (in Russian).
- Титова Н.В., Чаудури К.Р. Немоторные симптомы болезни Паркинсона: подводная часть айсберга. Анналы неврологии 2017; 4: 1–14 / Titova N.V., Chauduri K.R. Non-motor symptoms of Parkinson's disease: the underwater part of the iceberg. Annals of Neurology 2017; 4: 1–144 (in Russian).
- Каракулова Ю.В., Гольченко Е.А., Яковлева Е.А. Взаимосвязь вегетативных и нервно-психических расстройств при болезни Паркинсона. Медицинский альманах 2022; 2 (21): 34–39 / Karakulova Yu.V., Golchenko E.A., Yakovleva E.A. Interconnection of vegetative and neuropsychiatric disorders in Parkinson's disease. Medical Almanac 2022; 2 (21): 34–39 (in Russian).
- Halli-Tierney A.D., Luker J., Carroll D.G. Parkinson Disease. Am Fam Physician. 2020; 102 (11): 679–691. PMID: 33252908.
- Antonini A., Odin P., Kleinman L., Skalicky A., Marshall M., Sail K., Onuk K. Implementing a Delphi Panel to Improve Understanding of Patient Characteristics of Advanced Parkinson’s Disease. Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders, San Diego, California, United States, June 14–18, 2015.
- Левин О.С., Федорова Н.В. Болезнь Паркинсона. М.: МЕДпрессинформ 2014; 384 / Levin O.S., Fedorova N.V. Parkinson's disease. Moscow: MEDpressinform 2014; 384 (in Russian).
- Fahn S., Poewe W. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Movement Disorders 2015; 30 (1): 1–3.
- Резолюция заседания Совета экспертов «Развернутая стадия болезни Паркинсона. Возможности перехода на инвазивные методы лечения». Москва, 16 декабря 2016 г. Журнал неврологии и психиатрии им. C.C. Корсакова 2017; 117 (5): 117–118. doi: 10.17116/jnevro201711751117-118. – EDN YTANPN. / Resolution of the meeting of the Council of Experts "Advanced stage of Parkinson's disease. Opportunities for switching to invasive therapies". Moscow, December 16, 2016. S.S. Korsakov Journal of Neurology and Psychiatry 2017; 117 (5): 117–118. doi: 10.17116/jnevro201711751117-118. – EDN YTANPN (in Russian).
- Odin P., Chaudhuri K.R., Slevin J.T., Volkmann J., Dietrichs E., Martinez-Martin P., Krauss J.K., Henriksen T., Katzenschlager R., Antonini A., Rascol O., Poewe W. National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism & Related Disorders 2015; 21 (10): 1133–44.
- Rohani M., Fasano A. Focused ultrasound for essential tremor: review of the evidence and discussion of current hurdles. Tremor and Other Hyperkinetic Movements (New York, N.Y.) 2017; 7: 462.
- Галимова Р.М., Иллариошкин С.Н., Бузаев И.В., Качемаева О.В. Терапия двигательных нарушений методом фокусированного ультразвука под контролем магнитно-резонансной томографии: рекомендации для врачей-неврологов по отбору пациентов. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений 2020; 1: 9–15 / Galimova R.M., Illarioshkin S.N., Buzaev I.V., Kachemaeva O.V. Therapy of motor disorders by the method of focused ultrasound under the control of magnetic resonance imaging: recommendations for neurologists on the selection of patients. Bulletin of the National Society for the Study of Parkinson's Disease and Movement Disorders 2020; 1: 9–15 (in Russian).
- Бриль Е.В., Томский А.А., Гамалея А.А. и др. Электростимуляция субталамического ядра в лечении развернутых стадий болезни Паркинсона. Уральский медицинский журнал 2015; 2 (125): 14–19. EDN TQTZQJ / Bril E.V., Tomskiy A.A., Gamaleya A.A. i dr. Electrical stimulation of the subthalamic nucleus in the treatment of unfolded stages of Parkinson's disease. Ural Medical Journal 2015; 2 (125): 14–19. EDN TQTZQJ (in Russian).
- Magara A., Bühler R., Moser D., Kowalski M., Pourtehrani P., Jeanmonod D. First experience with MR-guided focused ultrasound in the treatment of Parkinson’s disease. Journal of Therapeutic Ultrasound 2014; 2: 11.
- Галимова Р.М., Набиуллина Д.И., Иллариошкин С.Н. и др. Первый опыт проведения таламотомии методом фокусированного ультразвука под контролем магнитно-резонансной томографии в России. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений 2022; 1: 3–8. doi: 10.24412/2226-079X-2022-12414. EDN SGQVEL / Galimova R.M., Nabiullina D.I., Illarioshkin S.N. i dr. The first experience of conducting thalamotomy by the method of focused ultrasound under the control of magnetic resonance imaging in Russia. Bulletin of the National Society for the Study of Parkinson's Disease and Movement Disorders 2022; 1: 3–8. doi: 10.24412/2226-079X-2022-12414. EDN SGQVEL (in Russian).
- Krishna V., Sammartino F., Rezai A. A review of the current therapies, challenges, and future directions of transcranial focused ultrasound technology: advances in diagnosis and treatment. JAMA Neurology 2018; 75 (2): 246–54.
- Alon Sinai, Yeshayahu Katz, Menashe Zaaroor, Olga Sandler, Ilana Schlesinger The Role of the Anesthesiologist during Magnetic ResonanceGuided Focused Ultrasound Thalamotomy for Tremor: A Single-Center Experience Hindawi Parkinson’s Disease. 2018; Article ID 9764807: 5.
- Ghanouni P., Pauly K.B., Elias W.J., Henderson J., Sheehan J., Monteith S., Wintermark M. Transcranial MRI-guided focused ultrasound: a review of the technologic and neurologic applications. AJR. American Journal of Roentgenology 2015; 205 (1): 150–9.
- Ахмадеева Г.Н., Галимова Р.М., Набиуллина Д.И. Лечение акинетико-ригидной формы болезни Паркинсона, осложненной развитием флуктуаций и дискинезий, методом деструкции с помощью фокусированного ультразвука. Нервные болезни 2022; 4: 26–30. doi: 10.24412/2226-0757-2022-12936. EDN MTLDXQ / Ahmadeeva G.N., Galimova R.M., Nabiullina D.I. Lechenie akinetiko-rigidnoj formy bolezni Parkinsona, oslozhnennoj razvitiem fluktuacij i diskinezij, metodom destrukcii s pomoshch'yu fokusirovannogo ul'trazvuka. Nervnye bolezni 2022; 4: 26–30. doi: 10.24412/2226-0757-2022-12936. EDN MTLDXQ (in Russian).
- Gallay M.N., Moser D., Magara A.E., Haufler F., Jeanmonod D. Bilateral MR-guided focused ultrasound pallidothalamic tractotomy for Parkinson’s disease with 1-year follow-up. Frontiers in Neurology 2021; 12: 601153.
- Ильина (Латыпова) Г.Р., Залялова З.А. Леводопа/карбидопа гель для интестинального введения в лечении развернутых стадий болезни Паркинсона: мировой и собственный опыт. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений 2022; 2: 79–81. doi: 10.24412/2226-079X-2022-12440. EDN XOUWNZ / Ilyina (Latypova) G.R., Zalyalova Z.A. Levodopa/carbidopa gel for intestinal introduction in the treatment of advanced stages of Parkinson's disease: world and own experience. Bulletin of the National Society for the Study of Parkinson's Disease and Movement Disorders 2022; 2: 79–81. doi: 10.24412/2226-079X-2022-12440. EDN XOUWNZ (in Russian).
- Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. Кодирование по Международной статистической классификации болезней и проблем, связанных со здоровьем: G20. G21.1. G21.2. G23.1-23.3. G23.8. Возрастная группа: Взрослые: клинические рекомендации. М. 2021 / Parkinson's disease, secondary parkinsonism and other diseases manifested by Parkinson's syndrome. Coding according to the International Statistical Classification of Diseases and Related Health Problems: G20. G21.1. G21.2. G23.1-23.3. G23.8. Age group: Adults: clinical guidelines. Moscow 2021 (in Russian).
- Рудакова А.В., Скоромец А.А., Тимофеева А.А. Фармакоэкономические аспекты применения интестинального геля, содержащего леводопу и карбидопу, при развернутых стадиях болезни Паркинсона. Медицинские технологии. Оценка и выбор 2016; 1 (23): 74–79. EDN VSLJTB / Rudakova A.V., Skoromets A.A., Timofeeva A.A. Pharmacoeconomic aspects of the use of intestinal gel, containing levodopa and carbidopa, in the developed stages of Parkinson's disease. Evaluation and selection 2016; 1 (23): 74–79. EDN VSLJTB (in Russian).
- Залялова З.А., Латыпова Г.Р. Маршрутизация пациентов с болезнью Паркинсона, получающих лечение посредством инфузий леводопа/карбидопа интестинального геля (Дуодопа). Болезнь Паркинсона и расстройства движений: руководство для врачей по материалам IV Национального конгресса по болезни Паркинсона и расстройствам движений (с международным участием). Под ред. С.Н. Иллариошкина, О.С. Левина. М. 2017; 195–6 / Zalyalova Z.A., Latypova G.R. Routing of patients with Parkinson's disease receiving treatment by infusions of levodopa/carbidopa intestinal gel (Duodopa). Parkinson's Disease and Movement Disorders. Guidelines for Physicians on the Proceedings of the IV National Congress on Parkinson's Disease and Movement Disorders (with international participation). Eds. S.N. Illarioshkin, O.S. Levin. Moscow 2017; 195–6 (in Russian).
- Скоромец А.А. и др. Леводопа-карбидопа интестинальный гель в терапии больных с развернутыми стадиями болезни Паркинсона: результаты 12-месячного открытого исследования. Журн. неврол. и психиатр. им. С.С. Корсакова 2017; 117 (2): 22–31/ Scoromec A.A. i dr. Levodopa-carbidopa intestinal gel in the therapy of patients with advanced stages of Parkinson's disease: results of a 12-month open-label study. Journe. Neurol. and a psychiatrist. named after S.S. Korsakov 2017; 117 (2): 22–31 (in Russian).
- Fasano A. et al. Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the COSMOS study. Mov. Disord. 2021; 36 (8): 1853–62.
- Zhang X.R. et al. The advantages of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a systematic review. Drug Des. Devel. Ther. 2020; 14: 845–54
- Pahwa R., Aldred J., Merola A., Gupta N., Terasawa E., Garcia-Horton V., Steffen D.R., Kandukuri P.L., Bao Y., Ladhani O., Yan C.H., Chaudhari V., Isaacson S.H. Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson's disease: Post-hoc analyses from a large 54-week trial. Clin Park Relat Disord. 2022; 8: 100181. doi: 10.1016/j.prdoa.2022.100181. PMID: 36594071; PMCID: PMC9803946.
- Fasano A., Ricciardi L., Lena F., Bentivoglio A.R., Modugno N. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Eur Rev Med Pharmacol Sci. 2012; 16 (1): 79–89. PMID: 22338551.
- Ehlers C., Timpka J., Odin P., Honig H. Levodopa infusion in Parkinson's disease: Individual quality of life. Acta Neurol Scand. 2020; 142 (3): 248–254. doi: 10.1111/ane.13260. Epub 2020 May 22. PMID: 32383152.
- Fernandez H., Standaert D., Hauser R.A. et al. Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Final 12-Month, Open-Label Results. Mov Disord. 2015; 30: 500–508.
- Catalán M.J., Escribano P.M., Alonso-Frech F. Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features. Mov Disord. 2017; 32 (4): 624–625. doi: 10.1002/mds.26903. Epub 2017 Jan 24. PMID: 28116835.
- Regidor I., Santos-García D., Catalán M.I.J., Puente V., Valldeoriola F., Grandas F., Mir P., Parra J.C., Arbelo J.M. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. J Parkinsons Dis. 2019; 9 (1): 173–182. doi: 10.3233/JPD-181324. PMID: 30562907
- Chang F.C., Kwan V., van der Poorten D., Mahant N., Wolfe N., Ha A.D., Griffith J.M., Tsui D., Kim S.D., Fung V.S. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. J Clin Neurosci. 2016; 25: 41–5. doi: 10.1016/j.jocn.2015.05.059. Epub 2016 Jan 14. PMID: 26777085.
- Poewe W., Bergmann L., Kukreja P., Robieson W.Z., Antonini A. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. J Parkinsons Dis. 2019; 9 (3): 531–541. doi: 10.3233/JPD-191605. PMID: 31282424; PMCID: PMC6700622.
- Fernandez H.H., Boyd J.T., Fung V.S.C., Lew M.F., Rodriguez R.L., Slevin J.T., Standaert D.G., Zadikoff C., Vanagunas A.D., Chatamra K., Eaton S., Facheris M.F., Hall C., Robieson W.Z., Benesh J., Espay A.J. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord. 2018; 33 (6): 928–936. doi: 10.1002/mds.27338. Epub 2018 Mar 23. PMID: 29570853.
- Poewe W., Chaudhuri K.R., Bergmann L., Antonini A. Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. Neurodegener Dis Manag. 2019; 9 (1): 39–46. doi: 10.2217/nmt-2018-0034. Epub 2018 Dec 14. PMID: 30547712; PMCID: PMC6360350
Supplementary files
